国产精品久久久久久永久牛牛,55国产福利在线视频,成人午夜精品视频在线观看

目錄產品 » 穩定細胞系 » Human Recombinant Corticotropin Releasing Factor Receptor CRF1 Stable Cell Line
CHO-K1/CRF1/Gα15 Stable Cell Line

Figure 1. CRH-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/CRF1/Gα15 cells. The cells were loaded with Calcium-4 prior to being stimulated with agonist CRH. The intracellular calcium change was normalized and measured by FLIPR. The relative fluorescent units (RFU) were normalized and plotted against the log of the cumulative doses of CRH (Mean ± SEM, n = 3). The EC50 of CRH on this cell was 13.19 nM.

Notes:
EC50 value is calculated with four parameter logistic equation:
Y=Bottom + (Top-Bottom) / (1+10^((LogEC50-X)*Hill Slope))
X is the logarithm of concentration. Y is the response
Y is % stimulation of RFU and starts at Bottom and goes to Top with a sigmoid shape.

CHO-K1/CRF1/Gα15 Stable Cell Line

Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with urocortin in CHO-K1/CRF1/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/CRF1/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of urocortin on CHO-K1/CRF1/Gα15 cells was 0.14 nM.

CHO-K1/CRF1/Gα15 Stable Cell Line

Recombinant CHO-K1 cells stably overexpress human corticotropin releasing hormone receptor 1 (CRF1) on the surface and contain high levels of G protein Gαs to couple with the receptor in downstream signaling pathways.
M00343
詢價

聯系我們
Product Description Recombinant CHO-K1 cells stably overexpress human corticotropin releasing hormone receptor 1 (CRF1) on the surface and contain high levels of G protein Gαs to couple with the receptor in downstream signaling pathways.
Culture Properties Adherent
Stability Stable through more than 16 passages with no significant changes in assay performance or expression profile.
Size Two vials of frozen cells (>1×106 per vial in 1 mL)
Storage Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received.

Culture Medium Ham’s F-12K (Kaighn’s), 10% FBS, 400 μg/ml Geneticin (Cat. No. 10131-035, Life Technologies), 100 μg/ml Hygromycin B (Cat. No. 10687010, Invitrogen)
Complete Growth Medium Ham’s F-12K (Kaighn’s), 10% FBS
Freeze Medium-DATA 45% Ham’s F-12K (Kaighn’s) (Cat. No. 21127, Life Technologies), 45% FBS (Cat. No. 10099-141, Gibco), 10% DMSO (Cat. No. D2650, Sigma)

  • CHO-K1/CRF1/Gα15 Stable Cell Line
  • CHO-K1/CRF1/Gα15 Stable Cell Line

    Figure 1. CRH-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/CRF1/Gα15 cells. The cells were loaded with Calcium-4 prior to being stimulated with agonist CRH. The intracellular calcium change was normalized and measured by FLIPR. The relative fluorescent units (RFU) were normalized and plotted against the log of the cumulative doses of CRH (Mean ± SEM, n = 3). The EC50 of CRH on this cell was 13.19 nM.

    Notes:
    EC50 value is calculated with four parameter logistic equation:
    Y=Bottom + (Top-Bottom) / (1+10^((LogEC50-X)*Hill Slope))
    X is the logarithm of concentration. Y is the response
    Y is % stimulation of RFU and starts at Bottom and goes to Top with a sigmoid shape.

  • CHO-K1/CRF1/Gα15 Stable Cell Line
  • CHO-K1/CRF1/Gα15 Stable Cell Line

    Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with urocortin in CHO-K1/CRF1/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/CRF1/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC50 of urocortin on CHO-K1/CRF1/Gα15 cells was 0.14 nM.


For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.


喜歡新升級的網站嗎?

討厭

不喜歡

一般

喜歡

非常喜歡

*
    主站蜘蛛池模板: 林州市| 克东县| 保定市| 都安| 东阿县| 舟曲县| 桐柏县| 辛集市| 兴仁县| 福泉市| 隆子县| 和静县| 株洲县| 固镇县| 偏关县| 哈密市| 皮山县| 麟游县| 双峰县| 台江县| 翼城县| 炉霍县| 毕节市| 卫辉市| 江达县| 曲阳县| 象州县| 邵武市| 保亭| 大理市| 宜宾市| 巴林右旗| 锡林郭勒盟| 旬邑县| 阳信县| 富源县| 金阳县| 满城县| 黄山市| 交口县| 台北市|